A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

OBJECTIVE To characterize the natural progression of infantile-onset Pompe disease. STUDY DESIGN Retrospective chart reviews of 168 patients with documented acid alpha-glucosidase deficiency and symptom onset by 12 months of age; Kaplan-Meier analysis of total and ventilator-free survival time; Cox proportional hazards regression modeling of mortality risk factors. RESULTS The median age at symptom onset was 2.0 months (range 0 to 12 months), 4.7 months at diagnosis (range: prenatal to 4.2 months), 5.9 months at first ventilator support (range 0.1 to 31.1 months), and 8.7 months at death (range 0.3 to 73.4 months). Survival rates at 12 months of age were 25.7% overall and 16.9% ventilator-free; at 18 months 12.3% and 6.7%. Cardiomegaly (92%), hypotonia (88%), cardiomyopathy (88%), respiratory distress (78%), muscle weakness (63%), feeding difficulties (57%), and failure to thrive (53%) appeared after a median age of approximately 4.0 months. Multiple covariate analysis confirmed that early symptom onset increased risk of early death. CONCLUSION Despite frequent therapeutic interventions, infantile-onset Pompe disease remains lethal.

[1]  L. Sandkuijl,et al.  Glycogen Storage Disease Type II: Birth Prevalence Agrees with Predicted Genotype Frequency , 2000, Public Health Genomics.

[2]  W. Hop,et al.  Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human -Glucosidase From Milk , 2004 .

[3]  F. Martiniuk,et al.  Identification of two subtypes of infantile acid maltase deficiency. , 2000, The Journal of pediatrics.

[4]  K. Hsiao,et al.  Pompe's disease in Chinese and prenatal diagnosis by determination of α-glucosidase activity , 1987, Journal of Inherited Metabolic Disease.

[5]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[6]  D. Cox,et al.  Analysis of Survival Data. , 1986 .

[7]  M. Kroos,et al.  Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling , 1999, European Journal of Human Genetics.

[8]  D. Cox Regression Models and Life-Tables , 1972 .

[9]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[10]  W. Hop,et al.  Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up , 2004, Annals of neurology.

[11]  J. Edwards THE EPIDEMIOLOGY OF CONGENITAL MALFORMATIONS. , 1964, Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften.

[12]  A F Roche,et al.  CDC growth charts: United States. , 2000, Advance data.

[13]  W. Rom,et al.  Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. , 1998, American journal of medical genetics.

[14]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[15]  A. Vulto,et al.  Recombinant human α-glucosidase from rabbit milk in Pompe patients , 2000, The Lancet.